Pruritus intensity is associated with cholestasis biomarkers and quality of life measures after maralixibat treatment in children with Alagille syndrome
Gonzales, E et al., Poster Presentation, AASLD 2020
View Publication
Natural variability of pruritus in Alagille syndrome; an analysis from the ICONIC study utilizing the Itch Reported Outcome Observer (ItchRO[Obs]) tool
Foster, B et al., Poster Presentation, AASLD 2020
View Publication
Serum bile acid control in long-term maralixibat-treated patients is associated with native liver survival in children with progressive familial intrahepatic cholestasis due to bile salt export pump deficiency
Thompson, R et al., Podium Presentation, EASL 2020
View Publication
Psychometric evaluation of the Adult Itch Reported Outcome tool, a worst itch numeric rating scale in adults with cholestatic liver disease
Foster, E et al., Poster Presentation, EASL 2020
View Publication
Differential expression of bile acid subspecies with maralixibat treatment in pruritus responders with bile salt export pump deficiency
Zhao, E et al., Poster Presentation, EASL 2020
View Publication
Genotype and dose-dependent response to maralixibat in patients with bile salt export pump deficiency
Thompson, R et al., Podium Presentation, AASLD 2019
View Publication
Durability of Treatment Effect with Long-Term Maralixibat in Children with Alagille Syndrome: 4-Year Safety and Efficacy
Gonzales, E et al., Podium Presentation, AASLD 2019
View Publication
Safety and efficacy of maralixibat in patients with primary sclerosing cholangitis: an open-label proof-of-concept study
Bowlus, C et al., Poster Presentation, AASLD 2019
View Publication
Dose-dependent fecal bile acid excretion with apical sodium-dependent bile acid transporter inhibitors maralixibat and volixibat in a dose-ranging phase 1 study in overweight and obese adults
Martin, P et al., Poster Presentation, AASLD 2019
View Publication
Phase 2 placebo-controlled withdrawal study of the ASBT inhibitor maralixibat in children with Alagille syndrome
Gonzales, E et al., Podium Presentation, EASL 2019
View Publication
Growth analysis in children with PFIC treated with the ASBT inhibitor maralixibat
Thompson, R et al., Podium Presentation, EASL 2019
View Publication
A Randomized, Controlled, Phase 2 Study of Maralixibat in the Treatment of Itching Associated With Primary Biliary Cholangitis
Mayo et al., Hepatol Commun. 2019 Mar; 3(3): 365–381.
View Publication
Placebo-Controlled Randomized Trial of an Intestinal Bile Salt Transport Inhibitor for Pruritus in Alagille Syndrome, Hepatology Communications
Shneider BL et al., 2018, 2(10)
View Publication
Phase 2 open-label efficacy and safety study of the apical sodium-dependent bile acid transporter inhibitor maralixibat in children with progressive familial intrahepatic cholestasis: 48-week interim efficacy analysis
Thompson, R, Podium Presentation, AASLD 2017
View Publication
A long-term phase 2 safety and efficacy study of the apical sodium-dependent bile acid transporter inhibitor maralixibat in children with Alagille syndrome: preliminary results from the IMAGINE study
Thompson, R, Podium Presentation, AASLD 2017
View Publication
Results of ITCH, A Multi-center Randomized Double-blind Placebo-controlled Trial of Maralixibat, an Intestinal Bile Salt Transport Inhibitor, for Pruritus in Alagille Syndrome
Shneider, BL et al., Podium Presentation, AASLD 2017
View Publication